News Related to DARZALEX FASPRO®

Related coverage linked through entity extraction aliases.

FDA Approves Two Johnson & Johnson Multiple Myeloma Regimens in Early 2026

Mar 06, 2026

The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.

FDA Approves Tecvayli Combo, Accepts Iberdomide NDA for Relapsed/Refractory Myeloma

Mar 06, 2026

The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.